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based longitudinal HIV cascade-of-care study in 
KwaZulu-Natal, South Africa
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Summary
Background Standard approaches to estimation of losses in the HIV cascade of care are typically cross-sectional and 
do not include population-based stages before linkage to clinical care. We used indiviual-level longitudinal cascade 
data, transition-by-transition, including population stages, both to identify the health-system losses in the cascade and 
to show the diﬀerences in inference between standard methods and the longitudinal approach.
Methods We used non-parametric survival analysis to estimate a longitudinal HIV care cascade for a large population 
of people with HIV residing in rural KwaZulu-Natal, South Africa. We linked data from a longitudinal population 
health surveillance (which is maintained by the Africa Health Research Institute) with patient records from the local 
public-sector HIV treatment programme (contained in an electronic clinical HIV treatment and care database, 
ARTemis). We followed up all people who had been newly detected as having HIV between Jan 1, 2006, and 
Dec 31, 2011, across six cascade stages: three population stages (first positive HIV test, HIV status knowledge, and 
linkage to care) and three clinical stages (eligibility for antiretroviral therapy [ART], initiation of ART, and therapeutic 
response). We compared our estimates to cross-sectional cascades in the same population. We estimated the 
cumulative incidence of reaching a particular cascade stage at a specific time with Kaplan-Meier survival  analysis.
Findings Our population consisted of 5205 individuals with HIV who were followed up for 24 031 person-years. We 
recorded 598 deaths. 4539 individuals gained knowledge of their positive HIV status, 2818 were linked to care, 
2151 became eligible for ART, 1839 began ART, and 1456 had successful responses to therapy. We used Kaplan-Meier 
survival analysis to adjust for censorship due to the end of data collection, and found that 8 years after testing positive 
in the population health surveillance, 16% had died. Among living patients, 82% knew their HIV status, 45% were 
linked to care, 39% were eligible for ART, 35% initiated ART, and 33% had reached therapeutic response. Median 
times to transition for these cascade stages were 52 months, 52 months, 20 months, 3 months, and 9 months, 
respectively. Compared with the population-based stages in the cascade, the transitions across the clinical stages were 
fast. Over calendar time, rates of linkage to care have decreased and patients presenting for the first time for care are, 
on average, healthier.
Interpretation HIV programmes should focus on linkage to care as the most important bottleneck in the cascade. 
Cascade estimation should be longitudinal rather than cross-sectional and start with the population-based stages 
preceding clinical care.
Funding Wellcome Trust, PEPFAR.
Introduction
The HIV cascade of care has been widely used to assess 
the scale-up of antiretroviral therapy (ART) for HIV, and 
has provided benchmarks for programme monitoring 
and highlighted opportunities for inter vention.1 The 
cascade describes discrete, consecutive stages through 
which people with HIV pass, including HIV testing, 
knowledge of HIV status, linkage to care, eligibility for 
ART,2–6 ART initiation, retention in care and viral load 
suppression.3,4,6–8 Because each stage in the cascade 
depends on the previous stage, missing one stage will in 
general result in failure to benefit from ART. At the 
population level, failure along the cascade results in loss 
of life for people with HIV (an estimated 1·1 million 
deaths globally in 2015),9–11 increased HIV transmission,12 
and substantial economic burdens.13,14 As evidence 
supporting earlier ART initiation15,16 and treatment as 
prevention17 accumulates, identification of failure points 
along the cascade is becoming more important. 
Unfortunately, the success of the approaches and 
strategies based on the cascade concept, including those 
aiming to achieve the UNAIDS 90-90-90 targets,18 is 
threatened if cascade data are biased or incomplete.
We previously identified four problems19 common in 
studies of HIV care cascades: missing preclinical, 
population-based stages; failure to account for temporal 
biases; lack of longitudinal inference; and use of disparate 
data sources. Cross-sectional cascade analyses are likely 
to yield biased inference because they do not account for 
both the changing composition of patients between 
stages and the time taken to transition from one stage to 
the next. Although in several studies, most notably those 
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by Nosyk and colleagues20 in 2015 and Alvarez-Uria and 
colleagues2 in 2013, longitudinal data have been used for 
cascade analysis, our analysis is the first to use 
longitudinal, individual-level data across all stages of the 
cascade, from infection to therapeutic response.
We aimed to use, for the first time, a truly longitudinal 
cascade, transition-by-transition, including population 
stages, both to identify the health-system losses in the 
cascade and to show the diﬀerences in inference between 
standard methods and the longitudinal approach. We 
apply survival analysis to data from a longitudinal 
population health surveillance, which has been linked to 
clinical HIV programme data, to assess health-system 
gaps in a rural region with a high prevalence of HIV 
infection in KwaZulu-Natal, South Africa. Whereas cross-
sectional cascades focus on the proportion of people in 
stages, we focus on the flow between stages. Most 
previous studies focused on the clinical stages of the 
cascade, but ours includes both the population-based and 
the clinical cascade stages.
Methods
Study site and population
Our study population was individuals with HIV living 
within a 438 km² area in the mostly rural subdistrict of 
Hlabisa in KwaZulu-Natal, South Africa. The study area 
is located near the market town of Mtubatuba; the 
prevalence of HIV infection in the area is high—around 
30% among adults.21,22 
The Africa Health Research Institute (AHRI), one of the 
Wellcome Trust’s five major overseas programmes, 
operates a comprehensive, longitudinal population 
health surveillance, which includes HIV testing, in the 
study area.23 All individuals aged 15–50 years who tested 
positive for HIV between Jan 1, 2006, and Dec 31, 2011, 
were included in the study and followed up until Jan 27, 
2014.  There are 17 HIV treatment and care clinics in 
Hlabisa subdistrict, most of which began distributing 
free ART between 2004 and 2007.23 The definition for 
individual eligibility for ART changed during the study 
period (table 1).9,24–26
Data collection
For this analysis, we linked two longitudinal data 
sources: the population health surveillance, which is 
maintained by the AHRI, and the electronic clinical HIV 
treatment and care database ARTemis, which is managed 
by the Hlabisa Department of Health and the AHRI. The 
population health surveillance system is based on a 
series of longitudinally linked annual surveys of all 
individuals 15 years or older who live in the surveillance 
area. The surveys include HIV testing, questions about 
knowledge of HIV status, and questions regarding 
sexual and health-care seeking behaviours.23 HIV test 
results generated in the surveys are not disclosed to 
participants. The ARTemis database is derived from the 
local Department of Health clinic-based HIV treatment 
and care information system, which contains data for 
Research in context
Evidence before this study
We did a targeted search based on a previous review and 
critique of the literature about the HIV cascade of care that we 
published. The primary source of evidence reviewed for this 
Article was the reference list for that paper, which includes 
both current and historical context for the construction of the 
HIV cascade; the methods review of that paper covers 
peer-reviewed published work, conference proceedings, and 
governmental institution publications. In most cascade 
analyses, cross-sectional designs are used to identify gaps in 
care, but cross-sectional analyses are likely to be biased as a 
result of violations of synthetic cohort and long-term 
steady-state assumptions. We noted a lack of comprehensive 
longitudinal cascade data. Of the few longitudinal cascades 
identified, all contained only the clinical cascade stages and 
therefore could not be used to identify losses in the preclinical 
stages. No cascade analysis had been done that followed up 
individuals longitudinally over all phases of the cascade from 
time of infection before knowledge of status, through status 
knowledge, linkage to care, ART initiation, and recovery. 
Furthermore, of the analyses with longitudinal data, none 
fully leveraged serial survival analytic methods, which can 
provide a complete and detailed view of the cascade and 
reduce the need for model assumptions.
Added value of this study
In this Article, we address these limitations by presenting the 
first population-based longitudinal analysis of the entire HIV 
cascade of care. Beginning in 2006, after the initial rollout of 
antiretroviral therapy in South Africa’s public health system, we 
followed up individuals from HIV infection to therapeutic 
response. We used survival analyses serially between all cascade 
stages to characterise both the simple time to transition and 
the shape of the survival analytic transition curve, leading to 
improved inference on the losses occurring at each stage. These 
innovations allow us to strengthen the existing evidence and to 
identify initial linkage to care as the most substantial loss in the 
cascade, which would have been biased in, or entirely missing 
from, other cascade-of-care analyses.
Implications of all available evidence
The major implications of our findings are twofold. First, policy 
makers in rural communities in South Africa and the wider region 
should focus their eﬀorts on improvement of initial linkage to 
care, which was the most important gap identified in our study. 
Second, researchers should, whenever feasible, use longitudinal 
data and survival analytic methods in HIV cascade analyses, 
because inference based on cross-sectional analyses could lead to 
substantial bias in the identification of losses along the cascade.
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clinic visit dates and laboratory data for all patients 
enrolled in either pre-ART or ART in one of the 17 clinics 
within the uMkhanyakude subdistrict. We linked the 
ARTemis data at the individual level to the data in the 
AHRI population health surveillance system by using  a 
combination of individual identifiers.27
Ethical approval for data collection for both the AHRI 
population health surveillance system and ARTemis was 
obtained from the Biomedical Research and Ethics 
Committee of the University of KwaZulu-Natal. Written 
consent for data collection from these studies was 
obtained in Zulu, and included use of collected data for 
anonymous research.
Statistical analysis
We used Kaplan-Meier non-parametric survival analytic 
methods28 to estimate the HIV cascade on the basis of the 
combined data from the the AHRI population health 
surveillance system and the ARTemis clinical database. 
We estimated the time to reaching the next stage of the 
cascade. The events defining the diﬀerent cascade stages 
are described in table 1. Because viral load tests were not 
consistently done in the HIV treatment and care clinics 
during the analysis period, we used a composite definition 
of therapeutic success as having a CD4 count of more 
than 500 cells per µL or a single undetectable viral load 
(<200 copies per mL29). This definition thus incorporates, 
but diﬀers from, the WHO definition of undetectable 
viral load (<1000 copies per mL30).
We characterised the probability of an individual 
starting at one stage and transitioning to a subsequent 
stage with a Kaplan-Meier curve for each transition stage. 
The competing risk of mortality was considered failure to 
reach a subsequent stage. Patients who reached the last 
date of cohort follow-up were censored. Eligibility for an 
event was conditional on a previous event. Whereas 
many other studies define retention as binary concept 
(retained vs lost to follow-up), we demonstrated the full 
variability of retention by showing the number of clinical 
visits at all times before transition. Deaths and retention 
events were counted in each transition for each 
individual, if they occurred between the beginning and 
ending stage, so that death and retention are attributable 
to a specific transition.
All percentages throughout this study represent 
percentages located on Kaplan-Meier curves. Each point 
on the curves is the cumulative incidence of an event on 
a particular day, expressed as the percentage of all those 
eligible for the event on day 0 who have attained the 
event by that particular later day. The area above the 
cumulative incidence curve between the y-axis and a 
vertical line that is perpendicular to the x-axis and crosses 
the x-axis on a particular day is the expected number of 
person-years between the initial stage event and the 
subsequent event.
People were allowed to have more than one transition 
on the same day, and were included in the denominator 
for each stage transition. In an extreme example, if a 
person were to test positive for HIV on day 0, and their 
next recorded event was a CD4 count of 150 cells per µL 
60 days later, they would appear as having transitioned 
simultaneously to HIV status knowledge, linkage to care, 
and ART eligibility stages 60 days after first testing 
positive. This updating of information conceptually 
preserves the conditionality of the cascade, which 
requires that individuals have to go through each stage to 
reach the next stage.
The population-based view of HIV testing includes all 
HIV testing sources and facilities. Our data for cascade 
attainment and progression from both population-based 
and clinical records ensure that so-called side doors31 into 
the cascade were captured comprehensively. Analytically, 
each new transition starts on the day when the event 
defining eligibility to this transition has occurred, 
irrespective of the pathway that led a person to that event. 
This approach correctly accounts for both side doors into 
the cascade and skipped and simultaneous transitions. 
For instance, an individual would not contribute person-
time to the transition between linkage to care 
and eligibility, if this individual had simultaneously 
transitioned to linkage and to eligibility. We also 
quantified the magnitude of skipped transitions by 
Definition Estimation
First positive HIV test Patient tested positive for HIV 
for the first time
Date of first recorded positive HIV test in AHRI 
population health surveillance system
HIV status knowledge Patient knows their HIV status Annual individual surveys within the AHRI 
population health surveillance system cohort 
include a question about whether individuals know 
their HIV status; all who respond “yes” are recorded 
as knowing their status on this date; all who have a 
clinical event (HIV-related clinic visit, laboratory 
test, or initiation of ART) associated with HIV 
status knowledge are recorded as knowing their 
status (on the date of the event)
Linkage to care Patient engages with formal 
health-care sector for 
HIV-related health care
Date of first recorded HIV clinic visit, registration 
at an HIV clinic, clinical CD4 cell count, viral load 
count, or ART initiation
Eligibility for ART Patient qualifies for ART, 
according to the South African 
national HIV treatment 
guidelines at that time
Date of first CD4 cell count that meets eligibility 
criteria for ART at the time of observation*
Initiation of ART Patient starts to take ART Date of the first ART prescription or dispensing; 
on the basis of ARTemis data
Therapeutic response Virological suppression or 
immunological recovery, 
or both
Date of first instance after ART initiation of CD4 
count >500 cells per µL or undetectable viral load 
(<200 copies per mL)
The first denominator is “first tested positive”; it is a criterion for inclusion of individuals from the AHRI population 
health surveillance system in the analyses. The subsequent denominators are also the events used in the survival 
analyses of each cascade stage to define time to event. For instance, those who enter the study analysis on the date 
when they “first tested positive” are then observed in their time to the event “HIV status knowledge”; those included in 
the denominator “HIV status knowledge” are then observed in their time to the event “linkage to care”, and so on. 
ART=antiretroviral therapy. AHRI=Africa Health Research Institute. *CD4 cell count criteria for ART eligibility varied 
over time: August, 2004, to March, 2010, ≤200 cells per µL;26 April, 2010, to July, 2011, CD4 count ≤200 cells per µL and 
≤350 cells per µL for patients who were pregnant or patients diagnosed with active tuberculosis; after July, 2011, 
≤350 cells per µL for all individuals.9,24,25
Table 1: Definition of events that define cascade stages
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allowing transitions on day 0, with the proportion who 
skipped through this stage shown as the y intercept in 
the Kaplan-Meier graphs.
The proportion of individuals reaching each stage from 
the time of testing positive was estimated by the Kaplan-
Meier estimator, adjusting for time censorship, each day 
up to 8 years after first testing positive for HIV. We 
compare this longitudinal cascade estimate with 
estimated cross-sectional cascades. The cross-sectional 
estimates are based on the last known stage status of 
individuals in our study population who were alive at the 
end of each year between 2006 and 2013.
Role of the funding source
The funders of the study had no role in study design; 
data collection, analysis, or interpretation; or writing of 
the Article. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
5205 individuals who tested positive for HIV at least once 
in the dataset were included in the analyses and contributed 
a total of 24 031 person-years of observation time (table 2). 
We recorded 598 deaths. 4539 individuals gained 
knowledge of their positive HIV status, 2818 were linked to 
care, 2151 became eligible for ART, 1839 initiated ART, and 
1456 had a successful response to therapy. 3780 patients 
(73%) were female; the mean age of participants was 
33 years (table 2). The CD4 cell count at first presentation 
to the ART programme increased with calendar time, from 
a mean of 270 cells per µL (SD 212) in 2006–07 to a mean 
of 309 cells per µL (SD 220) in 2010–11 (table 2).
Over time, individuals transition towards downstream 
stages in the cascade. Because the speed of this 
downstream transition can vary substantially over 
calendar time (eg, because ART becomes available in 
increasingly many clinics), the cross-sectional cascade 
view can be misleading—for instance, it can substantially 
and consistently underestimate the true rate of cascade 
progression, because the denominator of a cascade 
estimate has increased rather than because transition 
speed to the next cascade stage has decreased (figure 1).
At the time of initial detection in the surveillance, 67% 
(95% CI 65–68) of individuals knew their HIV status, 
25% (24–27) had been linked to care, 15% (14–16) were 
eligible for ART, 13% (12–13) had begun ART, and 7% 
(6–8) had reached therapeutic response after initiation 
(appendix p 2). 2 years after first testing positive, 66% 
(64–68) knew their status, 25% (23–26) were linked to 
care, 16% (15–17) were eligible for ART, 12% (11–13) had 
initiated ART, and 10% (9–11) had therapeutically 
responded (appendix p 3). These data are a conservative 
estimate of time to event from initial infection, because 
infection must have occurred before detection. Less than 
50% of individuals are expected to have transitioned to 
any stage in the cascade beyond knowing HIV status 
within 8 years of testing positive in the surveillance 
(among those who had not reached later stages at initial 
detection; appendix pp 3, 4).
The rates of transition diﬀer substantially across the 
cascade stages. Overall, the transitions in the population-
based stages are slower than those across the later clinical 
stages (figure 2). Patients who are eligible for care typically 
began ART within a few months of testing eligible, with a 
median time to transition of about 3 months. Similarly, 
once initiated, the median individual reached therapeutic 
response within a year. Median time to transition from first 
testing positive for HIV test to knowing HIV status was 
52·1 months (95% CI 47·6–57·9), from status knowledge to 
linkage to care was 51·9 months (48·4–56·4), linkage to 
care to ART eligibility was 19·5 months (17·0–22·3), ART 
eligibility to ART initiation was 3·1 months (2·8–3·4), and 
ART initiation to therapeutic response was 9·3 months 
(8·6–10·2; appendix p 5).
Importantly, the transitions through the two population-
based stages of the cascade  slowed down over calendar 
All (2006–11) 2006–07 2008–09 2010–11
Female sex 73% (0·45) 73% (0·45) 71% (0·45) 74% (0·44)
Age, years 33·0 (12·4) 33·2 (12·9) 33·4 (12·8) 32·4 (11·6)
Years of education 8·09 (3·61) 7·87 (3·77) 7·91 (3·72) 8·44 (3·35)
Married ever 27% (0·44) 30% (0·46) 26% (0·44) 25% (0·43)
Currently employed 31% (0·46) 34% (0·47) 30% (0·46) 29% (0·46)
Ever pregnant* 83% (0·38) 82% (0·38) 82% (0·38) 84% (0·36)
First CD4 count (cells per µL) 299 (222) 270 (212) 305 (230) 309 (220)
N 5205 1712 1575 1918
Data are mean (SD). Binary variables (female, married ever, and pregnant ever) were expressed as percentages. 
*Percentage of female population.
Table 2: Characteristics of patients, by year of first positive HIV test
Figure 1: Kaplan-Meier graphs of longitudinal cascade vs annual cross-sectional cascades
Bars represent cross-sectional cascades generated on the basis of the last known stage of cascade progression on 
Dec 31 of each year. The red lines show the percentage of individuals reaching each stage up to 8 years after first 
testing positive for HIV. 95% CIs from of the Kaplan-Meier estimates are shown as brackets on the red lines. 
ART=antiretroviral therapy. 
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time (figure 2). By contrast, individuals who have started 
treatment seemed to be responding faster in later than in 
earlier years, with median time to therapeutic response of 
12 months (95% CI 9–13) among those who initiated ART 
in 2006–07 and 9 months (95% CI 8–10) among those who 
initiated ART in 2010–11 (appendix p 5). In the appendix, 
we also summarise time-to-transition data in an alternative 
form (p 6): we show the percentage of people who have 
reached the next cascade stage 2 and 4 years after reaching 
the present stage. 
The longitudinal cascade in figure 2 is useful because it 
focuses on the cumulative incidence of transitioning 
across individual cascade stages, but does not contain 
detail on which stages people move to, or about subsequent 
stages. Figure 3 shows skipped transitions and 
simultaneous transitions across several cascade stages. 
As calendar time progressed, deaths occurred at 
increasingly later stages in the cascade (figure 3; appendix 
p 7). Retention was very high among people who were 
linked to care, particularly among those who began ART 
(figure 3). Furthermore, retention improved over calendar 
time, with increasing large percentages of people having 
either transitioned to the next stage or making additional 
clinic visits without transitioning (figure 3).
To examine the overall eﬀect of changing ART eligibility 
guidelines in South Africa, we constructed the HIV 
treatment cascade over calendar time, rather than over 
time since first detection of an individual with HIV 
(appendix p 1). Although the early stages of the cascade 
did not seem to be aﬀected by changes to guidelines for 
ART eligibility in South Africa, we noted small increases 
in the proportions of people reaching later cascade stages 
(ART eligibility, ART initiation, and therapeutic response), 
which could be explained by the guideline changes.
Discussion
We used an individually linked longitudinal cascade of 
care from time of HIV detection in the population to 
clinical therapeutic response to show that linkage to care 
is the most important bottleneck in the HIV cascade in 
rural KwaZulu-Natal. Our population-based and 
longitudinal analysis of the cascade provides crucial 
insights that would not have been generated from either 
cross-sectional or facility-based cascade analyses.
One key finding is that the early stages of the cascade 
diﬀer substantially in character from the later stages. In 
the early stages before treatment eligibility is known, 
transitions are slow and unpredictable. Individuals tend 
not to transition for long times, but when they do, they 
often do so in rapid succession across several cascade 
stages. Once individuals are known to be eligible for ART, 
transitions tend to occur rapidly and predictably.
Figure 2: Transition to each stage by year—single state transitions
n=5205. Columns from left to right represent cascade stage transitions; rows from top to bottom show the years in which entry transition event occurred. For 
example, the chart in the fourth column, second row, is the transition from “eligible for ART” to “initiated ART” for patients who became eligible for ART between 
2008 and 2009 among those who had not yet initiated ART, for up to 4 years after reaching eligibility for ART. ART=antiretroviral therapy. 
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Comparison of longitudinal and cross-sectional analyses 
shows how the latter can be misleading. The repeated 
cross-sectional cascades we constructed as an alternative 
to longitudinal analysis imply improvement in the cascade 
with time. However, much of that improvement is 
attributable to the passage of calendar time, rather than 
health-systems improvement. This insight becomes 
apparent only with longitudinal cascade analysis.
The longitudinal cascade contains all cross-sectional 
perspectives that are possible during the observation 
period, in addition to the cascade’s development over 
time. Thus longitudinal cascades will always be better 
than otherwise-equivalent cross-sectional cascades. 
However, cross-sectional cascade analyses are likely to 
remain useful because the data needed for their 
construction are easier, quicker, and cheaper to collect. 
Data collection systems for national-level cascades might 
necessitate substantial financial commitment and long-
term collaboration across many clinical and research sites. 
The data for this study came from one of Africa’s largest 
and longest-running population-based and longitudinal 
public health surveillance systems. For other longitudinal 
cascade analyses, less resource-intensive data collection 
will probably be suﬃcient, but individual-level longitudinal 
data for cascade events requires substantial investment in 
data collection. When such investments are not feasible, 
cross-sectional cascades are the next-best option to inform 
policy and programmatic decisions.
Our findings complement and advance those of 
previous work on the HIV treatment cascade. In an 
important previous study,32 Nsanzimana and colleagues 
estimated the cross-sectional cascade from multiple data 
sources for Rwanda. One of the main conclusions of that 
work—that major losses in cascade progression occur at 
the stage of linkage to care—also holds true in our study, 
which was in a very diﬀerent context. Our study 
substantially strengthens the evidence for this finding, 
because we were able to estimate the cascade for the first 
time both longitudinally and on the basis of individually 
linked data across all cascade stages (rather than cross-
sectional comparisons of cascade stages estimated by 
combining aggregate denominator and numerator data 
from diﬀerent sources19). Our findings also complement 
with direct measurement the indirect evidence provided 
Figure 3: Transition to each stage by year, including entrance and exit stages, retention, and mortality
n=5205. The intercept in this figure shows the percentage of people who have already transitioned across subsequent cascade stages the first time they are detected 
in the denominator of a particular cascade stage. These intercepts thus represent the percentages of people who skip cascade stages or simultaneously transition 
across several stages. Each blue-shaded striation represents the cumulative incidence of reaching a cascade stage subsequent to the one that is represented by thick 
black lines in each panel of this figure. The percentage of people who have had a given number of additional clinic visits before transitioning is shown in green—the 
darker the shade of green, the more clinic visits. The cumulative incidence of death before the next transition is shown in pink, and the white area represents the 
proportion of people at each timepoint who are alive, have not made any additional clinic visits, and have not transitioned to a subsequent cascade stage.
ART=antiretroviral therapy.
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by Siedner and colleagues,33 who inferred that barriers to 
“presentation, diagnosis, and linkage to HIV care remain 
major challenges” in sub-Saharan Africa on the basis of 
the fact that CD4 cell count at the point of linkage to care 
did not increase significantly between 2002 and 2013.
Counterintuitively, as the rollout of HIV interventions 
expands and services improve, some measures of health-
systems performance can seem to worsen. One 
reasonable explanation for this eﬀect is population 
dynamics. Early in the rollout of ART, there is a backlog 
of individuals who had been ill for some time. These 
patients are likely to link quickly to newly available HIV 
care. Individuals reaching a given cascade stage in later 
years are more likely to have been infected more recently 
and, as a result, less likely to have symptoms of HIV, 
which could reduce the motivation to engage in care. 
CD4 cell counts at first presentation in our population 
steadily increased with time, consistent with the findings 
of other studies in South Africa.33 Other factors, such as 
underlying beliefs and psychological traits, socioeconomic 
status, and physical access to health services, are probably 
changing over time with respect to newly infected and 
detected individuals, and could also be contributing to 
the slowing of linkage over time.
Our data have several important limitations. The second 
stage in our analyses (ie, knowledge of HIV status) is 
measured on the day of a self-report of HIV status rather 
than on the actual day when patients became aware of 
their status. However, because we gathered data annually, 
the underestimation of the cumulative incidence of 
individuals who gained HIV status knowledge should not 
be very large. Another limitation is that some people 
eligible for HIV testing in the surveillance cannot be 
contacted in a specific year or refuse to test for HIV. 
However, over 5 years, more than 80% of eligible 
individuals tested for HIV at least once in the study 
population,34 ensuring that, during the observation period, 
most people with HIV were included in our sample. We 
would expect that people who do not test for HIV have 
even lower rates of linkage to care and other cascade 
progressions than those in our study, suggesting that our 
conclusions are likely to be conservative. A third limitation 
is that, although this analysis might show trends and 
changes, we do not quantitatively estimate the eﬀect of the 
causal mechanisms underlying those changes. Future 
analyses should be done to understand better the 
determinants of the speed of cascade progression.
Interventions increasingly need to promote HIV 
testing in early disease stages and linkage to care among 
people with HIV who have not yet taken up care. Options 
for improvements in HIV testing uptake include 
financial incentives and gifts for HIV testing,35 home-
based testing approaches, and testing with support from 
community health workers. HIV self-testing, which has 
become available in South Africa and several other 
countries in the region, could also contribute to increased 
knowledge of HIV status in people in early disease 
stages. Options for enhancement of linkage to care 
include interventions that address the major structural 
and behavioural barriers to HIV treatment uptake, 
including supply-side interventions (eg, subsidised 
transport to clinics and building of additional ART 
clinics) and demand-side interventions (eg, motivational 
counselling, financial incentives, and mobile phone 
reminders to link to care after a positive HIV test).
Scientists need to support eﬀorts to improve HIV 
testing and linkage to care through eﬀectiveness 
experiments of real-world applications of innovative 
approaches, rigorous imple mentation science, and 
qualitative studies to discover the underlying reasons 
why some subpopulations are at higher risk of not 
testing or linking to care than others. In addition to 
empirical studies of interventions complementing and 
enhancing existing models of HIV treatment and care, 
research into the eﬀect of novel models of HIV care, 
such as home-based ART initiation and integrated 
models of chronic disease care, is needed. Because 
funding for novel interventions and models of care will 
compete with other funding priorities, detailed (and 
ideally causally determined) cost data should be 
gathered in these studies. Importantly, as our results 
show, future studies of interventions and novel models 
of care should aim to esablish approaches to accelerate 
cascade progression and should be based on longitudinal 
outcomes data.
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